Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Merck
UBS
Moodys
Medtronic
Dow
AstraZeneca
US Army
Queensland Health

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,293,284

« Back to Dashboard

Which drugs does patent 8,293,284 protect, and when does it expire?

Patent 8,293,284 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty patent family members in five countries.
Summary for Patent: 8,293,284
Title:Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide
Abstract: The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.
Inventor(s): Baldassarre; James S. (Doylestown, PA), Rosskamp; Ralf (Chester, NJ)
Assignee: INO Therapeutics LLC (Hampton, NJ)
Application Number:12/821,041
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,293,284
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 8,293,284

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,293,284

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,112 Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation ➤ Try a Free Trial
8,282,966 Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide ➤ Try a Free Trial
8,795,741 Methods for treating patients who are candidates for inhaled nitric oxide treatment ➤ Try a Free Trial
8,431,163 Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,293,284

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009202685 ➤ Try a Free Trial
Australia 2010202422 ➤ Try a Free Trial
Australia 2010206032 ➤ Try a Free Trial
Australia 2012201382 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Chubb
McKinsey
Cipla
McKesson
Fuji
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.